Recro Pharma Inc (REPH.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||2008||Independent Chairman of the Board|
|61||2008||President, Chief Executive Officer, Director|
|58||2016||Chief Financial Officer|
|62||2017||Executive Vice President - Business Development|
|39||2017||Senior Vice President - Finance, Chief Accounting Officer|
- BRIEF-Recro Pharma secures $100 million credit facility
- BRIEF-Recro Pharma reports Q3 revenue $17.1 million
- BRIEF-Recro pharma says IV meloxicam 30mg demonstrates statistically significant reductions in pain
- BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG
- BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg